An Integrated in Silico 3D Model-Driven Discovery of a Novel, Potent, and Selective Amidosulfonamide 5-HT<sub>1A</sub> Agonist (PRX-00023) for the Treatment of Anxiety and Depression
Oren M. Becker(Epix Pharmaceuticals (United States)), Silvia Noiman(Epix Pharmaceuticals (United States)), Pradyumna Mohanty(Epix Pharmaceuticals (United States)), Dale Dhanoa(Epix Pharmaceuticals (United States)), Raphael Nudelman(Teva Pharmaceuticals (Israel)), Sharon Shacham(Roche (Switzerland)), Alexander Heifetz(Argonne National Laboratory), Anurag Sharadendu(Epix Pharmaceuticals (United States)), Srinivasa R. Cheruku(Epix Pharmaceuticals (United States)), Dongli Chen(Epix Pharmaceuticals (United States)), Yael Marantz(Epix Pharmaceuticals (United States)), Michael Kauffman(Roche (Switzerland)), Merav Fichman(Epix Pharmaceuticals (United States))
Cited by 141
Related Papers
OxyR
|Cell|2002|474
S-nitrosylation: spectrum and specificity
|Nature Cell Biology|2001|243
Drug Insight: tumor necrosis factor-converting enzyme as a pharmaceutical target for rheumatoid arthritis
|Nature Clinical Practice Rheumatology|2008|197
Phase IB Study of Selinexor, a First-in-Class Inhibitor of Nuclear Export, in Patients With Advanced Refractory Bone or Soft Tissue Sarcoma
|Journal of Clinical Oncology|2016|165
A nitric oxide processing defect of red blood cells created by hypoxia: Deficiency of S-nitrosohemoglobin in pulmonary hypertension
|Proceedings of the National Academy of Sciences|2005|132